SAREPTA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.2 USD | +6.09% |
|
+5.39% | +28.85% |
Presenter SpeechSalveen Richter (Analysts)Great. Good morning, everyone. Thanks for joining us...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
124.2
USD
Average target price
164.5
USD
Spread / Average Target
+32.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.85% | 11.66B | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.86% | 22.2B | |
| -16.53% | 21.23B | |
| -8.49% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| -24.93% | 8.22B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Transcript : Sarepta Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10
